Tango Therapeutics Q3 2022 net loss $29.1M; cash $393.3M; pipeline advances

Tango Therapeutics, Inc.

2022-Q3 EPS reported -$0.90 revenue$18,449,000

Net loss $29.1M ($0.33/share) vs $19.6M ($0.28) year ago; cash $393.3M sufficient into 2025.
TNG908 phase 1/2 trial enrolling; CTA approved in France; initial safety and efficacy data expected H1 2023.
Disclosed TNG260 as CoREST inhibitor for STK11-mutant cancers; IND filing on track for H1 2023.
Declared TNG348 development candidate for BRCA1/2-mutant cancers; IND filing planned for 2023.
Appointed Aaron Weitzman as CMO; R&D expenses $28.7M, G&A $8.1M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Tango Therapeutics, Inc. reported third quarter ended September 30, 2022 results: revenue $6.9 million.

Period: third quarter ended September 30, 2022
Revenue: $6.9 million
Result: reported results

Exact text from the filing

held $393.3 million in cash, cash equivalents and marketable securities, which the Company believes to be sufficient to fund operations into 2025. Collaboration revenue was $6.9 million for the three months ended September 30, 2022, compared to $6.8 million for the same period in 2021, and $18.4 million for the nine months ended September 30, 2022 compared to

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Tango Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-024215

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.